Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · BioMarin Pharmaceutical (BMRN)

BioMarin to acquire Amicus Therapeutics for $4.8 billion in all-cash deal

Neutral Impact 5 of 5 m&a Written later

BioMarin agreed to acquire Amicus Therapeutics for $14.50 per share in cash, a total equity value of approximately $4.8 billion, through a merger in which Amicus becomes a wholly owned subsidiary. The deal requires approval by Amicus stockholders and antitrust clearances, and is expected to close in the second quarter of 2026. BioMarin plans to fund it with cash on hand and approximately $3.7 billion of non-convertible debt, and the companies say it is expected to be accretive to non-GAAP diluted EPS in the first 12 months after close.

Key points

  • Price of $14.50 per Amicus share in cash, a 33% premium to Amicus' last close
  • Total equity value of approximately $4.8 billion; financing includes approximately $3.7 billion of non-convertible debt
  • Amicus pays BioMarin a $175 million termination fee in specified circumstances
  • Expected close in the second quarter of 2026; End Date of June 19, 2026, subject to automatic extensions

The filing

CompanyBioMarin Pharmaceutical (BMRN)
Form8-K, current report
Filed with the SECDec 19, 2025, 8:47 AM ET
Accession number0001193125-25-325856

Items reported: 1.01 Material Definitive Agreement7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on December 19, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.